糖基化
体内
药理学
化学
药代动力学
体外
变性(裂变材料)
药效学
受体
生物化学
生物物理学
生物
生物技术
核化学
作者
Ricardo J. Solá,Kai Griebenow
出处
期刊:BioDrugs
[Springer Nature]
日期:2010-02-01
卷期号:24 (1): 9-21
被引量:375
标识
DOI:10.2165/11530550-000000000-00000
摘要
During their development and administration, protein-based drugs routinely display suboptimal therapeutic efficacies due to their poor physicochemical and pharmacological properties. These innate liabilities have driven the development of molecular strategies to improve the therapeutic behavior of protein drugs. Among the currently developed approaches, glycoengineering is one of the most promising, because it has been shown to simultaneously afford improvements in most of the parameters necessary for optimization of in vivo efficacy while allowing for targeting to the desired site of action. These include increased in vitro and in vivo molecular stability (due to reduced oxidation, cross-linking, pH-, chemical-, heating-, and freezing-induced unfolding/denaturation, precipitation, kinetic inactivation, and aggregation), as well as modulated pharmacodynamic responses (due to altered potencies from diminished in vitro enzymatic activities and altered receptor binding affinities) and improved pharmacokinetic profiles (due to altered absorption and distribution behaviors, longer circulation lifetimes, and decreased clearance rates). This article provides an account of the effects that glycosylation has on the therapeutic efficacy of protein drugs and describes the current understanding of the mechanisms by which glycosylation leads to such effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI